<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293045</url>
  </required_header>
  <id_info>
    <org_study_id>ROU_COLHYD09</org_study_id>
    <secondary_id>2009-A01217-50</secondary_id>
    <nct_id>NCT01293045</nct_id>
  </id_info>
  <brief_title>Biological Bone Markers and Hydrolyzed Collagen Supplement in Menopausal Healthy Women</brief_title>
  <official_title>Study of Change in Biological Markers of Bone Metabolism Following Consumption of Hydrolyzed Collagen for 3 Months in Healthy, Non-osteoporotic, Menopausal Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nealth Sarl</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ROUSSELOT SAS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nealth Sarl</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Preliminary scientific studies, in both animals and humans suggest that oral consumption
           of hydrolyzed collagen acts on the bone remodeling process by stimulating the activity
           of osteoblasts responsible for bone formation while improving the bone mineral density
           and biomechanical resistance of long bones.

        -  The objective of this clinical research is to measure changes in biomarkers of bone
           turnover in postmenopausal healthy women, not osteoporotic, in response to consumption
           of hydrolyzed collagen for three months.

        -  For this, we propose to measure blood and urinary markers of formation and bone
           resorption before consumption, then 45 and 90 days after daily consumption of 10 g of
           hydrolyzed collagen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum C-terminal telopeptide of type 1 collagen (CTX)</measure>
    <time_frame>Day 45</time_frame>
    <description>MARKERS OF BONE RESORPTION : change from Baseline (Day 0) in serum CTX at 45 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary telopeptide N-terminal of type 1 collagen (NTX)</measure>
    <time_frame>Day 45</time_frame>
    <description>MARKERS OF BONE RESORPTION : change from Baseline (Day 0) in urinary NTX at 45 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum osteocalcin</measure>
    <time_frame>Day 45</time_frame>
    <description>MARKERS OF BONE FORMATION : change from Baseline (Day 0) in serum osteocalcin at 45 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bone alkaline phosphatase</measure>
    <time_frame>Day 45</time_frame>
    <description>MARKERS OF BONE FORMATION: change from Baseline (Day 0) in serum bone alkaline phosphatase at 45 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum amino-terminal pro-peptide of type 1 procollagen (P1NP)</measure>
    <time_frame>Day 45</time_frame>
    <description>MARKERS OF BONE FORMATION : change from Baseline (Day 0) in serum P1NP at 45 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary telopeptide N-terminal of type 1 collagen (NTX)</measure>
    <time_frame>Day 90</time_frame>
    <description>MARKERS OF BONE RESORPTION : change from Baseline (Day 0) in urinary NTX at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum osteocalcin</measure>
    <time_frame>Day 90</time_frame>
    <description>MARKERS OF BONE FORMATION : change from Baseline (Day 0) in serum osteocalcin at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bone alkaline phosphatase</measure>
    <time_frame>Day 90</time_frame>
    <description>MARKERS OF BONE FORMATION: change from Baseline (Day 0) in serum bone alkaline phosphatase at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum amino-terminal pro-peptide of type 1 procollagen (P1NP)</measure>
    <time_frame>Day 90</time_frame>
    <description>MARKERS OF BONE FORMATION : change from Baseline (Day 0) in serum P1NP at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-terminal telopeptide of type 1 collagen (CTX)</measure>
    <time_frame>Day 90</time_frame>
    <description>MARKERS OF BONE RESORPTION : change from Baseline (Day 0) in serum CTX at 90 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>HC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group of volunteers fed with Hydrolyzed Collagen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group of volunteers fed with wheat proteins</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>hydrolyzed collagen</intervention_name>
    <description>10g/day at breakfast during 90 days</description>
    <arm_group_label>HC Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>wheat protein</intervention_name>
    <description>10g/day at breakfast during 90 days</description>
    <arm_group_label>CT Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women

          -  Aged between 55 and 65 years

          -  Primary or secondary amenorrhea for at least 5 years

          -  BMI ≥ 20 kg/m2 and &lt; 27 kg/m2

          -  DXA &gt; 2.5 SD

          -  No history of fragility fracture bone

          -  Not under guardianship

          -  Not on hormone replacement or any osteoporotic therapy

          -  Covered by Social Security

          -  Negative serology for hepatitis B/C and HIV

          -  Written informed consent form signed.

        Exclusion Criteria:

          -  Bone density &lt; 2.5 SD (standard deviation)

          -  Endocrine disease

          -  No history of fragility fracture bone

          -  Dietary disorder (anorexia, bulimia)

          -  Hormone replacement therapy

          -  Inclusion in another clinical study

          -  Subjects receiving over 4,500 Euros in the last 12 months (including the present
             study)

          -  Subjects presenting risk of non-compliance in the opinion of the recruiting doctor.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert BENAMOUZIG, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherche en Nutrition Humaine d'Ile-de-France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRNH - Centre de Recherche sur Volontaires - Hôpital AVICENNE</name>
      <address>
        <city>Bobigny</city>
        <state>Seine-saint-denis</state>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Nomura Y, Oohashi K, Watanabe M, Kasugai S. Increase in bone mineral density through oral administration of shark gelatin to ovariectomized rats. Nutrition. 2005 Nov-Dec;21(11-12):1120-6.</citation>
    <PMID>16308135</PMID>
  </reference>
  <reference>
    <citation>Takeuchi Y, Nakayama K, Matsumoto T. Differentiation and cell surface expression of transforming growth factor-beta receptors are regulated by interaction with matrix collagen in murine osteoblastic cells. J Biol Chem. 1996 Feb 16;271(7):3938-44.</citation>
    <PMID>8632016</PMID>
  </reference>
  <reference>
    <citation>Wu J, Fujioka M, Sugimoto K, Mu G, Ishimi Y. Assessment of effectiveness of oral administration of collagen peptide on bone metabolism in growing and mature rats. J Bone Miner Metab. 2004;22(6):547-53.</citation>
    <PMID>15490264</PMID>
  </reference>
  <reference>
    <citation>Guillerminet F, Beaupied H, Fabien-Soulé V, Tomé D, Benhamou CL, Roux C, Blais A. Hydrolyzed collagen improves bone metabolism and biomechanical parameters in ovariectomized mice: an in vitro and in vivo study. Bone. 2010 Mar;46(3):827-34. doi: 10.1016/j.bone.2009.10.035. Epub 2009 Nov 4.</citation>
    <PMID>19895915</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2011</study_first_submitted>
  <study_first_submitted_qc>February 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2011</study_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Postmenopausal women</keyword>
  <keyword>Functional food</keyword>
  <keyword>Hydrolysed collagen</keyword>
  <keyword>Bone metabolism</keyword>
  <keyword>Bone marker of resorption</keyword>
  <keyword>Bone marker of formation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

